Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England | Zendy

Shamez Ladhani | Zendy; Nick Andrews | Zendy; Sydel R. Parikh | Zendy; Helen Campbell | Zendy; Joanne White | Zendy; Michael Edelstein | Zendy; Xilian Bai | Zendy; Jay Lucidarme | Zendy; Ray Borrow | Zendy; Mary Ramsay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

Author(s) -

Shamez Ladhani,

Nick Andrews,

Sydel R. Parikh,

Helen Campbell,

Joanne White,

Michael Edelstein,

Xilian Bai,

Jay Lucidarme,

Ray Borrow,

Mary Ramsay

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1901229

Subject(s) - booster (rocketry) , vaccination , immunization , meningococcal vaccine , group b , booster dose , meningococcal disease , medicine , vaccination schedule , virology , chickenpox vaccine , pediatrics , neisseria meningitidis , immunology , biology , varicella vaccine , antibody , physics , bacteria , genetics , astronomy

In September 2015, the United Kingdom introduced the multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded national immunization program at a reduced two-dose priming schedule for infants, with a 12-month booster.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research